Newsroom
Selected Publications
Value in Health. 2021;
24(2): pp. 244-249
“Health Technology Assessment with Diminishing Returns to Health: The Generalized Risk-Adjusted Cost Effectiveness (GRACE) Approach.”
Lakdawalla, Darius N. and Charles Phelps
A novel and mathematically rigorous framework for calculating cost-effectiveness when outcomes are uncertain and patients care about risk.
European Journal of Health Economics. 2021
“A Guide to Extending and Implementing Generalized Risk-Adjusted Cost-Effectiveness (GRACE).”
Lakdawalla, Darius N. and Charles Phelps
A presentation of generalized risk-adjusted cost-effectiveness (GRACE), an improvement upon traditional cost-effectiveness useful for predicting value of medical technology with uncertain outcomes.]
Statistics in Medicine. 2021;
40(25):5487-5500
“Penalized regression for left-truncated and right-censored survival data.”
McGough, Sarah F., Devin Incerti, Svetlana Lyalina, Ryan Copping, Balasubramanian Narasimhan, Robert Tibshirani
Evaluates statistical methods for prediction and validation of survival models with high-dimensional real-world clinicogenomic data.
hesim: arXiv preprint arXiv:2012.09437 (2021)
“Health Economic Simulation Modeling and Decision Analysis.”
Incerti, Devin, and Jeroen P. Jansen
Describes an open source software package, hesim, developed by the authors for simulating the value of medical technologies.
Health Economics. Published online October 7, 2020
“Predicting quantity and quality of life with the Future Elderly Model”
Ermini Leaf, Duncan, Bryan Tysinger, Dana P. Goldman, and Darius N. Lakdawalla
Validation of a pathbreaking microsimulation model that predicts health outcomes for a representative sample of Americans.
Value in Health, 2017; 20(7): pp. 866-875
“Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.”
Lakdawalla, Darius N., Jason Shafrin, Ningqi Hou, Desi Peneva, Seanna Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer and Robert Figlin
A novel statistical approach to estimating real-world effectiveness outcomes from clinical trial efficacy data.
Op-Eds
Harvard Business Review. 2015
“Understanding Health Care’s Short-Termism Problem”
Chandra, A. and D.P. Goldman
Health Affairs Blog. 2012
“When Epidemiology Goes Astray: Valuing Cancer Care In The United States And Europe”
Eber, M., D.P. Goldman, D.N., Lakdawalla, and T. Philipson
Health Affairs Blog. 2015
“Moving Beyond Price-Per-Dose In The Pharmaceutical Industry”
Goldman, D. and D.N. Lakdawalla
Health Affairs Blog. 2016
“Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement”
Goldman, D., S. Nussbaum, and M. Linthicum
Health Affairs Blog. 2015
“It’s Time For Value-Based Payment In Oncology”
Goldman, D.P., D.N. Lakdawalla, and L. Newcomer
Health Affairs Blog. 2012
“Harnessing The Promise Of Comparative Effectiveness Research,”
Goldman, D.P., et al.
Health Affairs Blog. 2018
“The Long Road To Value-Based Payment: The Case of Transcatheter Aortic Valve Replacement”
Mattke, S., D.N. Lakdawalla, and D.P. Goldman
Modern Healthcare. 2015
“Drop Medicaid ‘Best Price’ Drug Rules In Favor of Value-Based Strategies,”
Goldman, D.
STAT. 2019
“Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs,”
Chen, A. and D. Goldman
Wall Street Journal. 2019
“Health Care’s Killer App: Life Insurance”
Goldman, D.P. and D. Lakdawalla